{'fraction_non_alphanumeric': 0.04483430799220273, 'fraction_numerical': 0.03898635477582846, 'mean_word_length': 4.405263157894737, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Maternal plasma Elabela levels in intrauterine growth restriction

Öz Purpose: The aim of this study was to investigate the role of Elabela in the etiopathogenesis of intrauterine growth retardation (IUGR). Materials and Methods: The present prospective study included 43 healthy pregnant women and 46 pregnant women with IUGR. Maternal serum were collected from the control group and IUGR group at time of delivery. Elabela levels were analyzed in maternal serum through ELISA method. Results: Lower Elabela levels (IUGR: 1.09 (0.61 - 15.61) ng / mL and Control: 1.44 (0.37 - 31.33) ng / mL) were observed in IUGR patients compared to controls. Elabela levels were positively correlated with gestational week and neonatal weight. (r = 0.263, p = 0.013 and r = 0.259, respectively; p = 0.014). Conclusion: The present study serves as the first study revealing the role of the decrease in Elabela in maternal serum on the etiopathogenesis of IUGR. This suggests that Elabela could be a potential drug target in cases with IUGR.